DA-EPOCH-R in Burkitt Lymphoma: Is It Enough for High-Risk Disease?

J Clin Oncol. 2020 Nov 1;38(31):3722-3723. doi: 10.1200/JCO.20.01850. Epub 2020 Sep 15.

Authors

Mark Hertzberg¹, David J L Joske¹, Maher K Gandhi¹

Affiliation

¹ Mark Hertzberg, MBBS, PhD, Department of Haematology, Prince of Wales Hospital and University of New South Wales, Sydney, NSW, Australia; David J.L. Joske, MBBS, Department of Haematology, Sir Charles Gairdner Hospital, and University of Western Australia, Perth, WA, Australia; and Maher K. Gandhi, MBChB, PhD, Mater Research Institute, University of Queensland, and Princess Alexandra Hospital, Brisbane, QLD, Australia.

PMID: 32931401
DOI: 10.1200/JCO.20.01850

No abstract available

Publication types

Letter
Comment

MeSH terms

Adult
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Burkitt Lymphoma* / drug therapy
Cyclophosphamide / therapeutic use
Doxorubicin / therapeutic use
Etoposide / therapeutic use
Humans
Prednisone / therapeutic use
Vincristine / therapeutic use

Substances

Vincristine
Etoposide
Doxorubicin
Cyclophosphamide
Prednisone

Supplementary concepts

EPOCH protocol